ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Glucosamine as a regulator of O-GlcNAc signaling: linking metabolism to disease pathogenesis.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycosylation modification: a trigger for obesity and its complications?Molecular medicine (Cambridge, Mass.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGlucosamine, a naturally occurring amino sugar abundant in cartilage, has long been utilized as a dietary supplement to alleviate osteoarthritis (OA) and joint pain. Beyond its structural role in maintaining joint integrity, glucosamine is metabolized through the hexosamine biosynthetic pathway (HBP) to generate UDP-N-acetylglucosamine (UDP-GlcNAc), the indispensable donor substrate for protein O-linked N-acetylglucosamine (O-GlcNAc) modification.
findingsAccumulating evidence indicates that glucosamine-driven modulation of HBP flux and the consequent alteration of O-GlcNAcylation exert profound effects on cellular signaling, metabolic regulation, and inflammatory responses. These mechanisms extend far beyond musculoskeletal health, influencing the pathogenesis of diverse conditions such as rheumatoid arthritis (RA), diabetes, obesity, neuroinflammation, neurodegenerative disorders, sepsis, and cancer. Despite glucosamine's long-standing clinical use, its potential role as a metabolic regulator of O-GlcNAc cycling remains underexplored.
conclusionThis review integrates current insights into the molecular basis of glucosamine-enhanced O-GlcNAcylation, highlighting its implications for disease onset and progression, and proposing a broader therapeutic framework that positions glucosamine as a promising modulator of inflammation and systemic pathology.
Indexed as
Identifiers
41842977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.